LEADER 00921nam0-2200301 --450 001 9910922848003321 005 20250116174520.0 010 $a978-88-290-2246-5 020 $aIT$b2024-5921 100 $a20250116d2024----kmuy0itay5050 ba 101 0 $aita 102 $aIT 105 $a 001yy 200 1 $aProfessori di desiderio$eseduzione e rovina nel romanzo del Novecento$fValentina Sturli$gprefazione di Guido Paduano 210 $aRoma$cCarocci$d2024 215 $a166 p.$d22 cm 225 1 $aLingue e letterature Carocci$v429 610 0 $aNarrativa$aTemi [:] Seduzione$aSec. 20. 676 $a809.393543$v23 700 1$aSturli,$bValentina$0813919 702 1$aPaduano,$bGuido 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a9910922848003321 952 $a809.3935 STUV 01$b2024/12066$fFLFBC 959 $aFLFBC 996 $aProfessori di desiderio$94308468 997 $aUNINA LEADER 05919nam 22007455 450 001 9910686478003321 005 20251008142045.0 010 $a3-031-20537-5 024 7 $a10.1007/978-3-031-20537-8 035 $a(CKB)5840000000241914 035 $a(DE-He213)978-3-031-20537-8 035 $a(MiAaPQ)EBC7236612 035 $a(Au-PeEL)EBL7236612 035 $a(PPN)269659455 035 $a(MiAaPQ)EBC7236061 035 $a(EXLCZ)995840000000241914 100 $a20230410d2023 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aViral Drug Delivery Systems $eAdvances in Treatment of Infectious Diseases /$fedited by Ranjita Shegokar, Yashwant Pathak 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (X, 409 p. 53 illus., 47 illus. in color.) 311 08$a3-031-20536-7 320 $aIncludes bibliographical references and index. 327 $aGlobal health and Viral diseases past, present and Future -- Drug resistance and statistics and patent status -- cellular understanding viral diseases -- Viral: current treatment options -- Mucosal drug delivery strategies for antiviral intervention -- Micro, nano emulsions in viral -- Novel formulation approaches to treat Ebola- virus -- Ebola- drug delivery -- Polymers for Bio sensing Applications in antiviral therapy and diagnosis -- Nanotechnology: A Stepping Stone towards Viral Hepatitis Treatment and Prevention in Children -- Recent Developments in the Treatment of Influenza -- Covid 19: from molecular pathogenesis to potential repurposed treatments -- Nano drug delivery systems for Covid-19-drug delivery -- Exploring the link between malaria and Covid 19 -- Characterization of biofunctionalized nanoparticles in ID -- Covid- azithromycin-ritonavir -- Strategies to combat Covid-19 drug delivery -- Phytomolecules and NDDS Covid-19. 330 $aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The third volume of series is focused on viral drug delivery systems. Typically, virus attaches to the cells (referred as host cell) and releases its DNA or RNA inside the cell. In second stage, virus?s genetic material takes control of the cell and forces it to replicate the virus leading to onset of disease symptoms. DNA class of viruses include Herpes, Papilloma and Adeno viruses. RNA class of viruses include retroviruses, such as HIV immunodeficiency virus and SARS COV ? 2 / Corona virus. This book addresses recent developments in viral drug delivery systems. It covers many different aspects of viral infections, ways to treat them using modern drug delivery systems like nano particulate carriers. The choice of viral delivery systems mainly depends upon the type of virus, duration of life cycle, presence of drug resistance, cellular and mucosal interaction of virus, accordingly gene or non-gene drug delivery systems are selected. Besides that, this book also reports global dynamics of viral diseases, future predictions of infection rate, current treatment options, details of drug carriers like nanoemulsions, polymeric nanoparticles, role of biofunctionalization, and phyto-molecules in treatment of viral infections particularly herpes, Covid-19, Ebola, HIV/AIDS, influenza and viral hepatitis. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of viral drug delivery research. 606 $aDrug delivery systems 606 $aPharmaceutical chemistry 606 $aDiseases 606 $aPharmacology 606 $aEpidemiology 606 $aPharmacy 606 $aDrug Delivery 606 $aPharmaceutics 606 $aDiseases 606 $aPharmacology 606 $aEpidemiology 606 $aPharmacy 615 0$aDrug delivery systems. 615 0$aPharmaceutical chemistry. 615 0$aDiseases. 615 0$aPharmacology. 615 0$aEpidemiology. 615 0$aPharmacy. 615 14$aDrug Delivery. 615 24$aPharmaceutics. 615 24$aDiseases. 615 24$aPharmacology. 615 24$aEpidemiology. 615 24$aPharmacy. 676 $a615.6 676 $a616.91061 702 $aShegokar$b Ranjita 702 $aPathak$b Yashwant 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910686478003321 996 $aViral Drug Delivery Systems$93089348 997 $aUNINA